title: Prognostic value of cytokeratin 19 in hepatocellular carcinoma: A meta-analysis.
abstract: BACKGROUND
  Although many studies have investigated the relationship between cytokeratin 19 (CK-19) and hepatocellular carcinoma (HCC), the prognostic value of CK-19 in HCC remains inconclusive.
  
  
  METHODS
  Eligible studies were sought in PubMed, Embase, Web of Science, Cochrane Library and Wanfang databases. Pooled hazard ratios (HRs) and odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were calculated.
  
  
  RESULTS
  17 studies with 2943 patients were included in this meta-analysis. Meta-analysis results showed that CK-19 over-expression was significantly associated with overall survival (OS) (HR=1.60, 95% CI: 1.32-1.93, univariate analysis; HR=2.25, 95% CI: 1.79-2.83, multivariate analysis) and disease-free survival (DFS) (HR=1.68, 95% CI: 1.35-2.10, univariate analysis; HR=1.97, 95% CI: 1.54-2.53, multivariate analysis). Meanwhile, CK-19 over-expression was also correlated with decreased 1-year OS rate (OR=0.32, 95% CI: 0.21-0.50), 5-year OS rate (OR=0.44, 95% CI: 0.14-0.87) and 1-year DFS rate (OR=0.51, 95% CI: 0.34-0.76), but not with 5-year DFS rate (OR=0.62, 95% CI: 0.35-1.10). These results suggested that CK-19 over-expression was significantly associated with poor survival rate and early tumor recurrence rate in HCC patients.
  
  
  CONCLUSIONS
  CK-19 can serve as an indicator of poor prognosis as well as a novel target for treatment in HCC.
authors.affiliation: Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Jilin University, Changchun 130021, Jilin Province, China.
authors.forename: Da-wei
authors.initials: DW
authors.lastname: Sun
authors.affiliation: Department of Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
authors.forename: Ying-yi
authors.initials: YY
authors.lastname: Zhang
authors.affiliation: Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Jilin University, Changchun 130021, Jilin Province, China.
authors.forename: Xiao-dong
authors.initials: XD
authors.lastname: Sun
authors.affiliation: Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Jilin University, Changchun 130021, Jilin Province, China.
authors.forename: Yu-guo
authors.initials: YG
authors.lastname: Chen
authors.affiliation: Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Jilin University, Changchun 130021, Jilin Province, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Qiu
authors.affiliation: Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Jilin University, Changchun 130021, Jilin Province, China.
authors.forename: Min
authors.initials: M
authors.lastname: Ji
authors.affiliation: Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Jilin University, Changchun 130021, Jilin Province, China. Electronic address: lvguoyue@sina.com.
authors.forename: Guo-yue
authors.initials: GY
authors.lastname: Lv
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000175:diagnosis* / Q000235:genetics; D006801:Humans; D053539:Keratin-19 / Q000235:genetics*; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000235:genetics; D011379:Prognosis; D015996:Survival Rate
chemical_list: D053539:Keratin-19
keywords: Cytokeratin 19 (CK-19); Hepatocellular carcinoma (HCC); Meta-analysis; Prognosis